Clinical evaluation of autoantibody of splice variant of BARD1 in detection of ovarian cancer
- VernacularTitle:BARD1剪切变异体的自身抗体在卵巢恶性肿瘤诊断中的临床价值
- Author:
Zhijun YANG
;
Yanming JIANG
;
Guang YANG
;
Yuliang RAN
;
Zhihua YANG
;
Wei ZHANG
;
Jieqing ZHANG
;
Zhongmian PAN
;
Li LI
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
Tumor suppressor proteins;
Antigens,neoplasm;
Autoantibodies
- From:
Chinese Journal of Obstetrics and Gynecology
2008;43(9):680-684
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the value of autoantibody of breast cancer susceptibility 1 associated RING domain (BARD1) splice variant (OV-142) in detection of ovarian cancer.Methods We cloned OV-142 gene into plasmid pET-30b(+).The recombinant protein of OV-142 was expressed in pET30b(+) system and purified. The autoantibody of OV-142 was detected by indirect enzyme-linked immunosorbent assay (ELISA).Results We successfully constructed the recombinant plasmid of OV-142.The recombinant protein was expressed in pET-30b(+) system and purified.The purification rate of the recombinant protein was up to 90%.The relative amount of autoantibody of OV-142 detected by indirect ELISA was analyzed by receiver operating characteristic curve (ROC) and the cutoff value was determined.Combination of the autoantibody IgG of OV-142 and CA125 was analyzed by logistic regression. The sensitivity,specificity and accuracy was 71.4%,89.1%,and 81.9%,respectively,which were higher than IgG (41.3%,84.2%,66.8% ) and CA125( 61.1%,88.0%,77.1% ) when used alone each.Conclusions OV-142 is a splice variant of BARD1.It may be a potential immunotherapy target of ovarian cancer.Detection of autoantibody of OV-142 is a potent complementary tool of CA125 in ovarian cancerdiagnosis.
